Clinical Trials Logo

Deleterious PALB2 Gene Mutation clinical trials

View clinical trials related to Deleterious PALB2 Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT04584255 Recruiting - Breast Cancer Clinical Trials

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Start date: December 18, 2020
Phase: Phase 2
Study type: Interventional

This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations. The names of the study drugs involved in this study are: - Niraparib (Zejula) - Dostarlimab

NCT ID: NCT02760849 Active, not recruiting - Clinical trials for Hereditary Breast and Ovarian Cancer Syndrome

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

Start date: May 2, 2016
Phase: N/A
Study type: Interventional

This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer. Risk reducing salpingo oophorectomy (RRSO) is surgery to remove the fallopian tubes and ovaries at the same time. Interval salpingectomy with delayed oophorectomy (ISDO) is surgery to remove the fallopian tubes. It is not known whether ISDO works better than RRSO at lowering risk of ovarian cancer and improving the sexual function and psychosocial well-being in patients with genetic mutation.